This Clinical Reference Group (CRG) covers Haematopoietic Stem Cell Transplantation (HSCT) services. Also known as Blood and Marrow Transplantation (BMT), the intervention is used to treat a wide spectrum of haematological and, increasingly, non-haematological disorders. The most common clinical indications for HSCT are leukaemias, lymphomas and myeloma.
- Dr. Fiona Dignan, Chair
- Prof. Adrian Bloor, Clinical Member
- Dr. Charles Crawley, Clinical Member
- Prof. Andrew Gennery, Clinical Member
- Dr. Ram Malladi, Clinical Member
- Dr. Kim Orchard, Clinical Member
- Dr. Deborah Richardson, Clinical Member
- Dr. Giles Ratcliffe, PHE Lead
- Nick Duncan, Pharmacy Lead
- George Norton, Patient & Public Voice Representative
- Sue McGregor, Patient & Public Voice Representative
- Caitlin Farrow, Affiliate Member
- Dr. Rachel Pawson, Affiliate Member
- Prof. John Snowden, Affiliate Member
- Anna Kafkalias, Lead Commissioner
A key part of the CRG’s work is the delivery of the ‘products’ of commissioning. These are the tools used by the 10 Hub Commissioning Teams to contract services on an annual basis.
Service specifications are important in clearly defining the standards of care expected from organisations funded by NHS England to provide specialised care. The specifications have been developed by specialised clinicians, commissioners, expert patients and public health representatives to describe both core and developmental service standards. Core standards are those that all funded providers should be able to demonstrate, with developmental standards being those which may require further changes in practice over time to provide excellence in the field.
The following service specifications fall within the scope of this CRG:
- Severe Combined Immunodeficiency and Related Disorders Service (children) – in partnership with the Women and Children’s NPOC
- Haematopoietic Stem Cell Transplantation (Adult)
- Haematopoietic Stem Cell Transplantation (Children)
- Paroxysmal Nocturnal Haemoglobinuria Service (Adults and Adolescents)
A commissioning policy is a document that defines access to a service for a particular group of patients. A NICE Technology Appraisal Guideline on the same topic will replace, or be incorporated into, a commissioning policy as appropriate. These are important documents that are developed to ensure consistency in access to treatments nationwide.
The following policies fall within the scope of this CRG:
- Allogeneic Haematopoietic Stem Cell Transplant for Primary Immunodeficiencies (all ages)
- Second allogeneic haematopoietic stem cell transplant for relapsed disease
- Haematopoietic Stem Cell Transplantation (HSCT) – lymphoplasmacytic lymphoma
- Haematopoietic Stem Cell Transplantation (HSCT) (All Ages)
- Plerixafor for stem cell mobilisation in adults and children
- Defibrotide for severe veno-occlusive disease following stem cell transplant
- Treatments for Graft versus Host Disease (GvHD) following Haematopoietic Stem Cell Transplantation
- Use of therapeutic immunoglobulin in England